| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SARAF |
| Uniprot No | Q96BY9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 195-339aa |
| 氨基酸序列 | SDGQYSPPPYSEYPPFSHRYQRFTNSAGPPPPGFKSEFTGPQNTGHGATSGFGSAFTGQQGYENSGPGFWTGLGTGGILGYLFGSNRAATPFSDSWYYPSYPPSYPGTWNRAYSPLHGGSGSYSVCSNSDTKTRTASGYGGTRRR |
| 预测分子量 | 17.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SARAF重组蛋白的模拟参考文献示例(建议通过学术数据库核实实际文献)：
---
1. **文献名称**: *"SARAF regulates store-operated calcium entry by fine-tuning Orai1 activation"*
**作者**: Palty, R., et al.
**摘要**: 研究揭示了SARAF通过直接与Orai1通道相互作用，负向调控存储操作钙内流(SOCE)的分子机制，利用重组SARAF蛋白证明其通过抑制Orai1的过度激活维持钙稳态。
2. **文献名称**: *"Structural insights into SARAF-mediated calcium signaling termination"*
**作者**: Albarran, L., et al.
**摘要**: 通过重组SARAF蛋白的晶体结构解析，阐明了其C端结构域与STIM1的结合模式，提出SARAF作为终止SOCE的关键分子开关的模型。
3. **文献名称**: *"Recombinant SARAF expression rescues calcium dysregulation in CRISPR/Cas9-mediated knockout cells"*
**作者**: Jha, A., et al.
**摘要**: 在SARAF基因敲除的HEK293细胞中，外源性表达重组SARAF蛋白恢复了SOCE的动力学特性，证实其在钙信号反馈抑制中的必要功能。
4. **文献名称**: *"SARAF-dependent modulation of TRPC1/Orai1 complexes in vascular smooth muscle cells"*
**作者**: Deng, X., et al.
**摘要**: 利用重组SARAF蛋白的体外实验结合电生理学分析，证明SARAF通过调控TRPC1-Orai1复合物活性影响血管平滑肌细胞的钙依赖性收缩。
---
**备注**：以上文献为示例性质，建议通过PubMed、Google Scholar等平台以关键词“SARAF recombinant protein”“SOCE regulation”等检索最新研究。真实文献可能涉及SARAF的CRAC通道调控、疾病模型(如心血管或免疫疾病)中的功能研究。
**Background of SARAF Recombinant Protein**
SARAF (Store-Operated Calcium Entry-Associated Regulatory Factor) is a transmembrane protein involved in regulating store-operated calcium entry (SOCE), a critical mechanism for maintaining cellular calcium homeostasis. Discovered in 2012. SARAF interacts with key components of SOCE, such as STIM1 (stromal interaction molecule 1) and Orai1. which mediate calcium influx upon endoplasmic reticulum (ER) calcium depletion. SARAF acts as a negative regulator, fine-tuning SOCE to prevent excessive cytosolic calcium accumulation, which can lead to cellular dysfunction or apoptosis.
Structurally, SARAF contains a single transmembrane domain, with its N-terminus oriented intracellularly and C-terminus extracellularly. It features a conserved CRAC channel-regulatory domain, crucial for its interaction with STIM1. Dysregulation of SARAF has been implicated in pathological conditions, including cancer, cardiovascular diseases, and immune disorders, where aberrant calcium signaling contributes to disease progression.
Recombinant SARAF protein is engineered using expression systems like *E. coli* or mammalian cell cultures, ensuring proper post-translational modifications for functional studies. It serves as a vital tool for *in vitro* and *in vivo* research, enabling investigations into SOCE mechanisms, protein-protein interactions, and calcium-dependent signaling pathways. Additionally, recombinant SARAF aids in drug discovery, particularly for therapies targeting calcium dysregulation-related diseases. Its application spans structural biology, cellular physiology, and translational research, highlighting its importance in understanding calcium signaling networks and developing therapeutic interventions.
×
